User:Mr. Ibrahem/Belantamab mafodotin

Belantamab mafodotin, sold under the brand name Blenrep, is a medication used to treat multiple myeloma. It is used when other treatments are no longer effective. It is given by injection into a vein.

Common side effects include keratopathy, vision problems, nausea, fever, infusion reactions, and tiredness. Other side effects may include low platelets. Use in pregnancy may harm the baby. It is a monoclonal antibody joined to the cytotoxic agent monomethyl auristatin F (MMAF). The antibody binds to B-cell maturation antigen (BCMA) found on myeloma cells.

Belantamab mafodotin was approved for medical use in the United States and Europe in 2020. In the United States it costs about 8,800 USD per 100 mg vial as of 2022. In the United Kingdom this amount costs the NHS about £5700.